Attention Deficit and Disruptive Behavior Disorders 
Welcome,         Profile    Billing    Logout  

2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Attention Deficit and Disruptive Behavior Disorders
NCT02951754: Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder

Recruiting
4
600
RoW
Immediate-release Methylphenidate, Ritaline
Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordination for the Improvement of Higher Education Personnel
Attention Deficit Disorder With Hyperactivity
12/32
12/32
NCT01233856: Omega-3 Fatty Acids as an Adjunctive Therapy for Treatment in Attention-Deficit Hyperactivity Disorder (ADHD)

Recruiting
N/A
30
US
Lovaza, Placebo (corn oil).
Maimonides Medical Center, GlaxoSmithKline
Attention-Deficit/Hyperactivity Disorder
06/12
06/12

Download Options